Dr. Joanna M Rhodes is an Assistant Professor of Medicine at Rutgers Robert Wood Johnson Medical School. She received BA from Wesleyan University and then did a Masters in Medical Sciences at Boston University. After this, She worked at Dana Farber Cancer Institute as a Clinical Research Coordinator, and knew after that experience She wanted to pursue a career in hematologic malignancies. She completed my medical training at Stony Brook School of Medicine and subsequently did her residency training in Internal Medicine at New York Presbyterian Weill Cornell. She then went to the University of Pennsylvania for Hematology/Oncology fellowship where she also received a Masters of Science in Clinical Epidemiology with a focus in Pharmacoepidemiology. Dr. Joanna M Rhodes's research is focused on bringing new therapies, particularly novel targeted agents and immune-based therapies to patients with CLL and lymphomas. As treatment paradigms have changed, her research has also focused on understanding the toxicities of these novel therapies, including best management strategies, particularly in older patients or in patients who have other chronic medical conditions.
Dr. Joanna M Rhodes is an Assistant Professor of Medicine at Rutgers Robert Wood Johnson Medical School. She received BA from Wesleyan University and then did a Masters in Medical Sciences at Boston University. After this, She worked at Dana Farber Cancer Institute as a Clinical Research Coordinator, and knew after that experience She wanted to pursue a career in hematologic malignancies. She completed my medical training at Stony Brook School of Medicine and subsequently did her residency training in Internal Medicine at New York Presbyterian Weill Cornell. She then went to the University of Pennsylvania for Hematology/Oncology fellowship where she also received a Masters of Science in Clinical Epidemiology with a focus in Pharmacoepidemiology. Dr. Joanna M Rhodes's research is focused on bringing new therapies, particularly novel targeted agents and immune-based therapies to patients with CLL and lymphomas. As treatment paradigms have changed, her research has also focused on understanding the toxicities of these novel therapies, including best management strategies, particularly in older patients or in patients who have other chronic medical conditions.